126 related articles for article (PubMed ID: 38296192)
1. Next-Generation Sequencing Trends among Adult Patients with Select Advanced Tumor Types: A Real-World Evidence Evaluation.
Ferreira-Gonzalez A; Hocum B; Ko G; Shuvo S; Appukkuttan S; Babajanyan S
J Mol Diagn; 2024 Apr; 26(4):292-303. PubMed ID: 38296192
[TBL] [Abstract][Full Text] [Related]
2. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
[TBL] [Abstract][Full Text] [Related]
3. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
[TBL] [Abstract][Full Text] [Related]
4. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.
Zou D; Ye W; Hess LM; Bhandari NR; Ale-Ali A; Foster J; Quon P; Harris M
J Mol Diagn; 2022 Aug; 24(8):901-914. PubMed ID: 35688357
[TBL] [Abstract][Full Text] [Related]
6. Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States.
Bruno DS; Hess LM; Li X; Su EW; Patel M
JCO Precis Oncol; 2022 Jun; 6():e2100427. PubMed ID: 35737912
[TBL] [Abstract][Full Text] [Related]
7. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
[TBL] [Abstract][Full Text] [Related]
8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.
Canino F; Tornincasa A; Bettelli S; Manfredini S; Barbolini M; Moscetti L; Omarini C; Toss A; Tamburrano F; Antonelli G; Baglio F; Belluzzi L; Martinelli G; Natalizio S; Ponzoni O; Dominici M; Piacentini F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473737
[TBL] [Abstract][Full Text] [Related]
10. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing.
Sheinson DM; Wong WB; Flores C; Ogale S; Gross CP
JCO Oncol Pract; 2021 Nov; 17(11):e1774-e1784. PubMed ID: 34043456
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study.
Kang DW; Park SK; Yu YL; Lee Y; Lee DH; Kang S
ESMO Open; 2024 Jan; 9(1):102200. PubMed ID: 38194884
[TBL] [Abstract][Full Text] [Related]
12. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
Iams WT; Mackay M; Ben-Shachar R; Drews J; Manghnani K; Hockenberry AJ; Cristofanilli M; Nimeiri H; Guinney J; Benson AB
JAMA Netw Open; 2024 Jan; 7(1):e2351700. PubMed ID: 38252441
[TBL] [Abstract][Full Text] [Related]
14. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
[TBL] [Abstract][Full Text] [Related]
15. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of next-generation sequencing for bone and soft tissue sarcoma.
Gusho CA; Weiss MC; Lee L; Gitelis S; Blank AT; Wang D; Batus M
Acta Oncol; 2022 Jan; 61(1):38-44. PubMed ID: 34686105
[No Abstract] [Full Text] [Related]
17. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
Zazo S; Pérez-Buira S; Carvajal N; Plaza-Sánchez J; Manso R; Pérez-González N; Dominguez C; Prieto-Potin I; Rubio J; Dómine M; Lozano V; Mohedano P; Carcedo D; Carias R; Rojo F
Cancer Med; 2024 Feb; 13(3):e6827. PubMed ID: 38213074
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
19. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
[TBL] [Abstract][Full Text] [Related]
20. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
Paz-Ares L; Gondos A; Saldana D; Thomas M; Mascaux C; Bubendorf L; Barlesi F
Lung Cancer; 2022 May; 167():41-48. PubMed ID: 35397297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
